Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube

Hematology / Oncology CE Activities

Hematology / oncology blog

View Details

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.
  • Hematology / Oncology
  • Blog
DOWNLOAD
View Details

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).
  • Hematology / Oncology
  • Blog
DOWNLOAD
View Details

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.
  • Hematology / Oncology
  • Blog
DOWNLOAD

RMEI Presentations

RMEI DECISION SUPPORT AIDS

View Details

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

RSS Latest Hematology / Oncology Articles
  • Adjuvant Immunotherapy for Kidney Cancer — A New Strategy with New Challenges April 18, 2024
    Surgery with curative intent constitutes the standard of care for patients with advanced renal-cell carcinoma, yet more than 50% of patients with high-risk features will have disease recurrence. Two agents have been approved by the Food and Drug Administration (FDA) for adjuvant use after nephrectomy on the basis of a...
    Martin H. Voss, Robert J. Motzer
  • Retinoblastoma Origins and Destinations April 18, 2024
    The study of retinoblastoma has led to fundamental insights into carcinogenesis, cell-cycle regulation, the genetic basis of cancer, and tumor-suppressor genes, as well as to advances in therapy.
    David Cobrinik
  • Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma April 18, 2024
    Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 years, 91% of pembrolizumab-treated patients were alive, as compared with 86% of those who received placebo after surgery.
    Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B. Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M. Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stephane Oudard, Delphine Topart, Hans Hammers, Hiroshi Kitamura, David F. McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles, the KEYNOTE-564 Investigators*

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
  • Allergy & Immunology
  • 2021
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
  • Gastroenterology
  • 2021

Previously Published CE Activities

Copyright © 2024. RMEI Medical Education, LLC. All rights reserved​

Privacy | Terms of Use